Navigating obstacles impacting the sustainability of Medicare-funded wound care pricing: As the US population continues to age, costs for hard-to-heal wounds are expected to rise and negatively contribute to the long-term financial stability of Medicare, which is currently labelled a ‘high-risk’ program by the US Government Accountability Office. Within wound care, some skin substitutes, also known as cellular tissue products (CTPs), and now referred to as CAMPS (cellular, acellular, and matrix-like products), have demonstrated improved healing times and cost-effective usage. However, a dramatic increase in the number of CAMPs has led to controversy on reimbursement rates.